logo
  

LumiraDx's SARS-CoV-2 Ag Test Receives WHO Emergency Use Listing

LumiraDx Ltd. (LMDX), a diagnostics company, announced Friday that its rapid COVID-19 antigen assay, LumiraDx SARS-CoV-2 Ag Test has successfully received the Emergency Use Listing or EUL by the World Health Organization in their latest response effort to combat COVID-19.

The decision by the WHO to include the LumiraDx SARS-CoV-2 antigen test in its EUL was based on an essential set of available quality, safety, and efficacy and performance data.

The LumiraDx antigen test joins a select group of antigen tests the WHO has included in its EUL and represents the first microfluidic assay to meet the criteria.

The LumiraDx antigen test is a microfluidic immunofluorescence assay that delivers results for the direct and qualitative detection of nucleocapsid protein antigen in nasal swab specimens collected from the patient.

The test is used with the LumiraDx multi-assay Platform. It delivers rapid results at the point of care enabling physicians to immediately commence appropriate treatment and patient management to maximize health outcomes and minimize further spread of infection.

In clinical studies, the test demonstrated 95% positive agreement versus RT-PCR in patients tested within 12 days of the onset of symptoms.

LumiraDx, through a partnership with the Bill and Melinda Gates Foundation, has already distributed 5,000 Platforms in 49 African countries in various care settings.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Walt Disney's streaming service Disney+ is rolling out its much-anticipated new ad-supported subscription plan for Disney+ in the U.S. as part of its bid to stem the loss and make its streaming business profitable after the services posted a hefty operating loss of more than $1 billion in the third quarter. It is also raising pricing for its bundled subscription plans with Hulu, ESPN+ and live TV. The U.S. Food and Drug Administration announced the intended availability of base powder to make around 6 million bottles of specialty formula from Mexico as part of its efforts to meet the nationwide supply shortage caused by Abbott Nutrition recall. Reckitt Nutrition/Mead Johnson Nutrition will send an initial shipment of 331 thousand pounds of base powder for PurAmino Hypoallergenic Formula. Shares of Deutsche Telekom AG were gaining more than 1 percent in the morning trading in Germany after the telecom major on Thursday raised its fiscal 2022 earnings outlook again, despite reporting lower profit in its second quarter. Adjusted EBITDA AL, a key earnings metric, increased, while adjusted EBITDA AL margin dropped.
RELATED NEWS
Follow RTT